Herpes zoster in the age of focused immunosuppressive therapy

JAMA

Volumn 301, Issue 7, 2009, Pages 774-775

  Whitley, Richard J ^a,c   Gnann, John W ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c 303 CHB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; PREDNISONE; VARICELLA ZOSTER VACCINE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

EDITORIAL; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; VACCINATION; DRUG ANTAGONISM; NOTE; POSTHERPETIC NEURALGIA;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HERPES ZOSTER; HUMANS; INCIDENCE; NEURALGIA, POSTHERPETIC; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 60749087331     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.150     Document Type: Editorial

References (24)

1. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43(6):717-722.
2. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(4):1125-1133.
3. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-1265.
4. Kinder A, Stephens S, Mortimer N, Sheldon P. Severe herpes zoster after infliximab infusion. Postgrad Med J. 2004;80(939):26.
5. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431-1438.
6. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370-1375.
7. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA. 2009;301(7):737-744.
8. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpeszoster in adults infected with human immunodeficiency virus. Clin Infect Dis. l995;21(2):370-375.
9. Veenstra J, Krol A, van Praag RM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS. 1995;9(10):1153-1158.
10. Engels EA, Rosenberg PS, Biggar RJ; District of Columbia Gay Cohort Study, Multicenter Hemophilia Cohort Study. Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997. J Infect Dis. 1999;180(6):1784-1789.
11. Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant. 2008; 27(1):11-16.
12. Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis. 2008;10(4):260-268.
13. Herrero JI, Quiroga J, Sangro B, et al. Herpes zoster after liver transplantation. Liver Transpl. 2004;10(9):1140-1143.
14. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation. Am J Transplant. 2004;4(1):108-115.
15. Yawn BP, Saddier P, Wollan PC, St SauverJL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341- 1349.
16. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect. 2005;133(2):245-253.
17. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008;197(suppl 2): S207-S215.
18. Whitley RJ, Weiss H, Gnann J Jr, et al; The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo- controlled trial. Ann Intern Med. 1996;125(5):376-383.
19. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330(13):896-900.
20. Oxman MN, Levin M, Johnson G, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.
21. Gnann JW Jr. Vaccination to preventherpeszosterin olderadults. J Pain. 2008; 9(1)(suppl 1):S31-S36.
22. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Recomm Rep. 2008;57(28):779]. MMWR Recomm Rep. 2008;57(RR-5):1-30.
23. van derKlooster JM, Bosman RJ, Oudemans-van Straaten HM, etal. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med. 2003; 29(12):2327-2329.
24. Tai YJ, Kelly R. Pyoderma gangrenosum complicated by herpes simplex virus infection. Austalas J Dermatol. 2005;46(3):161-164.